ONCO (Onconetix) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


ONCO Onconetix Inc ONCO
23 GF Score
Price $0.98
! 4 Warning Signs
View Full Analysis

What is Onconetix Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Onconetix's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ONCO vs ISCO, VRAX, LYRA: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Onconetix's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Onconetix Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Onconetix's Margin of Safety % (DCF FCF Based) falls into.


ONCO
23GF Score
Onconetix Inc ONCO
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onconetix Business Description

Address 201 E. Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
23GF Score

Get the complete analysis for ONCO

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price